Other reports

Consolidated Cash Flow Statement

€ million

 

Note

 

2023

 

2022

Profit after tax

 

 

 

2,834

 

3,339

Depreciation/amortization/impairment losses/reversals of impairment losses

 

 

 

1,880

 

2,030

Changes in inventories

 

 

 

-89

 

-604

Changes in trade accounts receivable

 

 

 

-8

 

-413

Changes in trade accounts payable/refund liabilities

 

 

 

-43

 

101

Changes in provisions1

 

 

 

188

 

279

Changes in other assets and liabilities1

 

 

 

-755

 

-445

Neutralization of gains/losses on disposal of fixed assets and
other disposals

 

 

 

-150

 

-48

Other non-cash income and expenses

 

 

 

-72

 

21

Operating Cash Flow

 

16

 

3,784

 

4,259

 

 

 

 

 

 

 

Payments for investments in intangible assets

 

 

 

-216

 

-275

Payments from the disposal of intangible assets

 

 

 

136

 

38

Payments for investments in property, plant and equipment

 

 

 

-1,807

 

-1,531

Payments from the disposal of property, plant and equipment

 

 

 

19

 

21

Payments for investments in financial assets

 

 

 

-537

 

-364

Payments for acquisitions less acquired cash and cash equivalents
(net)

 

 

 

-12

 

-854

Proceeds from the disposal of other financial assets

 

 

 

510

 

219

Payments for the acquisition of non-financial assets

 

 

 

-2,494

 

-1,075

Proceeds from the disposal of non-financial assets

 

 

 

2,511

 

1,077

Payments from divestments

 

 

 

 

4

Investing Cash Flow

 

23

 

-1,892

 

-2,743

 

 

 

 

 

 

 

Dividend payments to shareholders of Merck KGaA, Darmstadt, Germany

 

 

 

-284

 

-239

Dividend payments to non-controlling interests

 

 

 

-12

 

-11

Profit withdrawal by E. Merck KG, Darmstadt, Germany

 

 

 

-868

 

-716

Proceeds from new borrowings of financial debt from E. Merck KG, Darmstadt, Germany and E. Merck Beteiligungen KG, Darmstadt, Germany, a related party 697 1,637 of E. Merck KG, Darmstadt, Germany

 

 

 

697

 

1,637

Repayment of financial debt to E. Merck KG, Darmstadt, Germany, and
E. Merck Beteiligungen KG, Darmstadt, Germany, a related party of
E. Merck KG, Darmstadt, Germany

 

 

 

-420

 

-1,613

Payments from new borrowings of other current and non-current financial debt2

 

 

 

519

 

1,281

Repayment of other current and non-current financial debt2

 

 

 

-1,364

 

-1,893

Financing Cash Flow

 

41

 

-1,732

 

-1,555

 

 

 

 

 

 

 

Changes in cash and cash equivalents

 

 

 

160

 

-39

Changes in cash and cash equivalents due to currency translation

 

 

 

-31

 

-7

Cash and cash equivalents as of January 1

 

 

 

1,854

 

1,899

Cash and cash equivalents as of December 31 (consolidated balance sheet)

 

35

 

1,982

 

1,854

1

Prior-year figures have been adjusted, see note (2) “Reporting principles”.

2

The lines “Repayments of bonds” and “Repayments of other current and non-current financial debt” as well as “Proceeds from the issuance of bonds” and “Payments from new borrowings of other current and non-current financial debt”, which were presented separately in the previous year, have been summarized to improve clarity.

Share this page: